AndreaBozzo/ceres-open-data-index huggingface dataset:
Statewide Data Indicator Syntax Zip File

This group of documents provides the syntax and supporting files in SPSS format that were used to calculate data quality and observed performance. Note: Syntax to calculate risk-standardized performance for each state uses a national, risk-adjusted model that requires child-level data from all states (i.e., national datasets) and thus cannot be replicated by states or other interested parties.

Metadata-only record linking to the original dataset. Open original dataset below.
The use of breast conserving surgery: linking insurance claims with tumor registry data

Background
          The purpose of this study was to use insurance claims and tumor registry data to examine determinants of breast conserving surgery (BCS) in women with early stage breast cancer.
        
        
          Methods
          Breast cancer cases registered in the Hawaii Tumor Registry (HTR) from 1995 to 1998 were linked with insurance claims from a local health plan. We identified 722 breast cancer cases with stage I and II disease. Surgical treatment patterns and comorbidities were identified using diagnostic and procedural codes in the claims data. The HTR database provided information on demographics and disease characteristics. We used logistic regression to assess determinants of BCS vs. mastectomy.
        
        
          Results
          The linked data set represented 32.8% of all early stage breast cancer cases recorded in the HTR during the study period. Due to the nature of the health plan, 79% of the cases were younger than 65 years. Women with early stage breast cancer living on Oahu were 70% more likely to receive BCS than women living on the outer islands. In the univariate analysis, older age at diagnosis, lower tumor stage, smaller tumor size, and well-differentiated tumor grade were related to receiving BCS. Ethnicity, comorbidity count, menopausal and marital status were not associated with treatment type.
        
        
          Conclusions
          In addition to developing solutions that facilitate access to radiation facilities for breast cancer patients residing in remote locations, future qualitative research may help to elucidate how women and oncologists choose between BCS and mastectomy.
Patent AT-E40071-T1: [Translated] ADJUSTABLE FORMWORK FOR MAKING CONCRETE ELEMENTS, SUCH AS STAIRS.

The present invention has as an object an adjustable mold for the manufacture of concrete elements such as staircases of the type having a straight line extent, of which the treads are perpendicular or not perpendicular to the risers. The adjustable mold according to the invention comprises a frame (1) on which is mounted a base (2), a front lateral wall, a back lateral wall (4) and two longitudinal walls (5), the said base being constituted by juxtaposed molding elements (6) each provided in a dihedral angle which dihedral angle is constituted by a wall intended to form the tread and by a wall intended to form the riser and is characterized in that each molding element (6) is supported by carriages mounted movably on horizontal guide rails (10) longitudinally to the mold, mounted on the frame (1) and in that a flexible strip (11) sealed to the concrete is stretched by stretchers (12) mounted at each extremity of the mold and is forced to cover and conform to the shape of the base (2) of the mold by winding on rollers (13), mounted beneath the base (2) each between two elements (6), and by gripping between the molding elements when these latter are maintained pressed the ones against the others by jacks.
Patent AT-E40180-T1: [Translated] REMOVAL BELOW LANDFILLS.

1. Tunnelling or excavation beneath dumps or deposits and renovation of such dumps or deposits and/or of other contaminated zones, characterized in that the working face is inclined by at least 30 degrees to the vertical as a soil slope and the tunnelling takes place by face working, the face workings of which have the form of side workings, wherein the working face (12), orientated in the direction of working, is inclined as a soil slope, a cutting shield (3) with projecting roof blades being used for driving the face workings, which shield possesses at one side an inclination corresponding to the slope of the working face (12), and sealing sheets (18) are laid on the floor, the edge of which sheets nearest the working face is continued sufficiently far into the excavation to make possible, after the parallel excavation, that is the next side working (20) has been completed, a connection with the sealing sheet (18) then laid in this side working.
Compound 530545: 3-Cyclopentylpropionic acid, decyl ester

Chemical compound data from PubChem database. IUPAC Name: decyl 3-cyclopentylpropanoate. Molecular Formula: C18H34O2. Molecular Weight: 282.5. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
NNDSS - Table 1D. Arboviral diseases, Western equine encephalitis virus disease to Babesiosis

NNDSS - Table 1D. Arboviral diseases, Western equine encephalitis virus disease to Babesiosis - 2020. In this Table, provisional cases* of notifiable diseases are displayed for United States, U.S. territories, and Non-U.S. residents.

Note: 
This table contains provisional cases of national notifiable diseases from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data from the 50 states, New York City, the District of Columbia and the U.S. territories are collated and published weekly on the NNDSS Data and Statistics web page (https://wwwn.cdc.gov/nndss/data-and-statistics.html). Cases reported by state health departments to CDC for weekly publication are provisional because of the time needed to complete case follow-up. Therefore, numbers presented in later weeks may reflect changes made to these counts as additional information becomes available. The national surveillance case definitions used to define a case are available on the NNDSS web site at https://wwwn.cdc.gov/nndss/. Information about the weekly provisional data and guides to interpreting data are available at: https://wwwn.cdc.gov/nndss/infectious-tables.html. 

Footnotes:
U: Unavailable — The reporting jurisdiction was unable to send the data to CDC or CDC was unable to process the data.
-: No reported cases — The reporting jurisdiction did not submit any cases to CDC.
N: Not reportable — The disease or condition was not reportable by law, statute, or regulation in the reporting jurisdiction.
NN: Not nationally notifiable — This condition was not designated as being nationally notifiable.
NP: Nationally notifiable but not published.
NC: Not calculated — There is insufficient data available to support the calculation of this statistic.
Cum: Cumulative year-to-date counts.
Max: Maximum — Maximum case count during the previous 52 weeks.
* Case counts for reporting years 2019 and 2020 are provisional and subject to change. Cases are assigned to the reporting jurisdiction submitting the case to NNDSS, if the case's country of usual residence is the U.S., a U.S. territory, unknown, or null (i.e. country not reported); otherwise, the case is assigned to the 'Non-U.S. Residents' category. Country of usual residence is currently not reported by all jurisdictions or for all conditions. For further information on interpretation of these data, see https://wwwn.cdc.gov/nndss/document/Users_guide_WONDER_tables_cleared_final.pdf.
†Previous 52 week maximum and cumulative YTD are determined from periods of time when the condition was reportable in the jurisdiction (i.e., may be less than 52 weeks of data or incomplete YTD data).
2011 CMHS Uniform Reporting System (URS) Output Tables for Arkansas

Center for Mental Health Services (CMHS) Uniform Reporting System (URS) Output Tables for 2011. The Uniform Reporting System (URS) is a state and national reporting system collected annually to support the Community Mental Health Services Block Grant program. State Mental Health Authorities report on National Outcome Measures (NOMS), evidence based practices, and utilization measures providing an overview of state mental health delivery systems.
The Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) trial

Previous trials (Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure [MERIT-HF], Cardiac Insufficiency Bisoprolol Study [CIBIS] II) have demonstrated a mortality benefit of β-adrenergic blockade in patients with mild to moderate heart failure. The recent Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) trial has extended these results to a more advanced patient population. This trial did not, however, include patients who could not reach compensation, patients with far advanced heart failure symptoms, or a significant number of black patients. Future studies of β-blockade may focus on these patients or patients with asymptomatic left ventricular dysfunction.
2012 Uniform Reporting System (URS) Tables for South Carolina

Center for Mental Health Services (CMHS) Uniform Reporting System (URS) Output Tables for 2012. The Uniform Reporting System (URS) is a state and national reporting system collected annually to support the Community Mental Health Services Block Grant program. State Mental Health Authorities report on National Outcome Measures (NOMS), evidence based practices, and utilization measures providing an overview of state mental health delivery systems.
National Health Interview Survey

<p>The National Health Interview Survey (NHIS) is the principal source of information on the health of the civilian noninstitutionalized population of the United States and is one of the major data collection programs of the National Center for Health Statistics (NCHS) which is part of the Centers for Disease Control and Prevention (CDC). The National Health Survey Act of 1956 provided for a continuing survey and special studies to secure accurate and current statistical information on the amount, distribution, and effects of illness and disability in the United States and the services rendered for or because of such conditions. The survey referred to in the Act, now called the National Health Interview Survey, was initiated in July 1957. Since 1960, the survey has been conducted by NCHS, which was formed when the National Health Survey and the National Vital Statistics Division were combined.<br />
NHIS data are used widely throughout the Department of Health and Human Services (DHHS) to monitor trends in illness and disability and to track progress toward achieving national health objectives. The data are also used by the public health research community for epidemiologic and policy analysis of such timely issues as characterizing those with various health problems, determining barriers to accessing and using appropriate health care, and evaluating Federal health programs.<br />
The NHIS also has a central role in the ongoing integration of household surveys in DHHS. The designs of two major DHHS national household surveys have been or are linked to the NHIS. The National Survey of Family Growth used the NHIS sampling frame in its first five cycles and the Medical Expenditure Panel Survey currently uses half of the NHIS sampling frame. Other linkage includes linking NHIS data to death certificates in the National Death Index (NDI).<br />
While the NHIS has been conducted continuously since 1957, the content of the survey has been updated about every 10-15 years. In 1996, a substantially revised NHIS questionnaire began field testing. This revised questionnaire, described in detail below, was implemented in 1997 and has improved the ability of the NHIS to provide important health information.</p>
Debate: Does it matter how you lower blood pressure?

Whether it matters how pressure is lowered has been debated since antihypertensive drugs proved to prevent cardiovascular events. However, in clinical trials, while the stroke benefit predicted by a given difference in blood pressure was achieved, the results for myocardial infarction were roughly half that expected. This suggested that adverse drug effects of diuretics and β-blockers might have detracted from their hypotensive effects. Trials with newer antihypertensive classes have revealed superior effects on outcomes associated with converting enzyme inhibitor use, and that α-blockers are less cardioprotective than diuretics. These studies establish that simple blood pressure reduction is an inadequate guide to therapy. The challenge now will be to determine the optimal therapy for each hypertensive patient.
Do bronchodilators have an effect on bronchiolitis?

Over the past 12 years there have been 12 randomised control trials, involving 843 infants, evaluating the effect of salbutamol or albuterol on bronchiolitis. Of these, nine (75%) showed that bronchodilators had no effect. In three studies a small transient improvement in the acute clinical score was seen. Ipratropium bromide had no significant effect. There have been five recent randomised trials involving 225 infants, evaluating the effect of nebulised adrenaline (epinephrine) on bronchiolitis. All five (100%) have shown significant clinical improvement, with reductions in oxygen requirement, respiratory rate and wheeze after nebulised adrenaline. Two showed lower hospital admission rates and earlier discharge with adrenaline. A significant improvement in pulmonary resistance was observed after nebulised adrenaline but not after salbutamol or albuterol. Currently there is no compelling evidence that bronchodilators have a role in the routine management of infants with bronchiolitis. There is better evidence for the use of nebulised adrenaline.
Compound 530447: 4-Butylbenzoic acid, 1-adamantylmethyl ester

Chemical compound data from PubChem database. IUPAC Name: 1-adamantylmethyl 4-butylbenzoate. Molecular Formula: C22H30O2. Molecular Weight: 326.5. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 528862: 4-Ethyl-2,3,5,6,7-pentathiaoctane

Chemical compound data from PubChem database. IUPAC Name: 1-(methyldisulfanyl)-1-(methyltrisulfanyl)propane. Molecular Formula: C5H12S5. Molecular Weight: 232.5. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Patent AT-E399737-T1: [Translated] DEVICE FOR SEALING ESCALATOR OR ESCALATOR DRIVES

The invention relates to an escalator or moving walkway that includes a drive shaft rotating at a relatively low peripheral speed around a horizontal axis and at least one sealing element associated with the drive shaft. Lubricant is supplied to the drive shaft and can escape from leakages at the one sealing element. A device is provided for a permanent recirculation of the lubricant escaping from the leakages. The device includes at least one conveyor element arranged downstream of the sealing element, seen in the direction of the leakage, and at least one recirculation element for the lubricant. The recirculation element cooperates with the conveyor element to return the lubricant into a region upstream of the at least one sealing element.
Managed Care Institutional Provider Network Data: March 31, 2015

The primary purpose for the Provider Network Data System is to collect data needed to evaluate the provider networks including physicians, hospitals, labs, home health agencies, durable medical equipment providers, etc., for all types of Managed Care plans in New York State, including HIV Special Need Plans (SNP), Family Health Plus (FHP) Buy-In, Programs of All-Inclusive Care for the Elderly (PACE), and Non-PACE Managed Long-Term Care (MLTC) plans. This dataset reflects institutional provider data. Provider Network Data System information is self reported. For more information, go to http://www.health.ny.gov/health_care/managed_care/.
Compound 525797: N-(4-Chlorophenyl)-N'-(4-bromophenyl)formamidine

Chemical compound data from PubChem database. IUPAC Name: N-(4-bromophenyl)-N'-(4-chlorophenyl)methanimidamide. Molecular Formula: C13H10BrClN2. Molecular Weight: 309.59. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 528018: Ethanol, 2,2-dichloro, 4-nitrobenzoate

Chemical compound data from PubChem database. IUPAC Name: 2,2-dichloroethyl 4-nitrobenzoate. Molecular Formula: C9H7Cl2NO4. Molecular Weight: 264.06. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 529736: 2-Butenedioic acid, 2-chloro-3-(dichloromethyl)-, dimethyl ester

Chemical compound data from PubChem database. IUPAC Name: dimethyl 2-chloro-3-(dichloromethyl)but-2-enedioate. Molecular Formula: C7H7Cl3O4. Molecular Weight: 261.5. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 525596: N,N-Dimethyl-N'-(4-ethoxyphenyl)-p-methoxybenzamidine

Chemical compound data from PubChem database. IUPAC Name: N'-(4-ethoxyphenyl)-4-methoxy-N,N-dimethylbenzenecarboximidamide. Molecular Formula: C18H22N2O2. Molecular Weight: 298.4. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
The dynamics of venous return and response to hypervolemia in the toad,

Background
          Venous return from the posterior region of amphibians travels by either two renal portal veins to the kidney or a central abdominal vein that drains into the hepatic portal system. The relative proportions of blood flow in these vessels has never been measured nor has a modification of flow been determined when venous return increases by changes in blood volume during hypervolemia or during increased volume input from the posterior lymph hearts.
        
        
          Results
          Venous return from the posterior region of Bufo marinus was measured under resting conditions and in response to a systemic hypervolemia. Doppler flow probes were positioned on the renal portal and ventral abdominal veins, and flow was recorded as injections of artificial plasma equaling 100% of the animal's plasma volume were administered through the sciatic artery. Resting flow was found to be 5.54 ± 2.03 ml min-1 kg-1 in the paired renal portal veins, and 7.31 ± 0.89 ml min-1 kg-1 in the ventral abdominal vein. While renal portal flow was found to increase by a factor of 2.4 times during the first 10 min of hypervolemia, ventral abdominal flow only increased by a factor of 1.3.
        
        
          Conclusions
          Our results quantify the contribution to circulation from posterior venous return in the toad Bufo marinus. A preferential movement of excess fluid through the renal portal pathway was also demonstrated, supporting the possibility of water elimination via the renal portal circulation, especially during periods of high water influx into the animals.
Continuous haemofiltration in the intensive care unit

Continuous renal replacement therapy (CRRT) was first described in 1977 for the treatment of diuretic-unresponsive fluid overload in the intensive care unit (ICU). Since that time this treatment has undergone a remarkable technical and conceptual evolution. It is now available in most tertiary ICUs around the world and has almost completely replaced intermittent haemodialysis (IHD) in some countries. Specially made machines are now available, and venovenous therapies that use blood pumps have replaced simpler techniques. Although, it remains controversial whether CRRT decreases mortality when compared with IHD, much evidence suggests that it is physiologically superior. The use of CRRT has also spurred renewed interest in the broader concept of blood purification, particularly in septic states. Experimental evidence suggests that this is a promising approach to the management of septic shock in critically ill patients. The evolution and use of CRRT is likely to continue and grow over the next decade.
Angiotensin receptor blockers in heart failure after the ELITE II trial

Specific blockers of the angiotensin type1 receptor, angiotensin receptor blockers (ARBs), have been introduced as an alternative to angiotensin-converting enzyme inhibitors (ACEi) for the treatment of heart failure. In comparison with ACEi, ARBs are better tolerated and have similar effects on haemodynamics, neurohormones and exercise capacity. Early studies have suggested that ARBs might have a superior effect on mortality. However, the first outcome trial, ELITE II (Losartan Heart Failure Survival Study), did not show any significant difference between losartan and captopril in terms of mortality or morbidity. This commentary outlines the role of ARBs in the treatment of heart failure.
2014 CMHS Uniform Reporting System (URS) Table for Republic of Marshall Islands

2014 Center for Mental Health Services (CMHS) Uniform Reporting System (URS) Output Tables for the Republic of Marshall Islands. The URS associated state reporting system is collected annually to support the Community Mental Health Services Block Grant program. Associated state Mental Health Authorities report on National Outcome Measures (NOMS), evidence based practices, and utilization measures providing an overview of state mental health delivery systems.
HepTracker Dashboard

This is the underlying dataset for HepTracker, which is an interactive dashboard and allows for the timely release of viral hepatitis data. HepTracker provides users the ability to view national case surveillance and viral hepatitis–related mortality data for hepatitis A, hepatitis B, and hepatitis C. Data available on the dashboard are from CDC’s National Notifiable Diseases Surveillance System (NNDSS) (https://www.cdc.gov/nndss/about/index.html) and the National Vital Statistics System (NVSS)(https://www.cdc.gov/nchs/nvss/index.htm). The dataset includes counts and rates for cases and deaths across multiple years, stratified by jurisdiction, race and ethnicity, age groups, and sex. Risk and exposure information is available for acute infections only. These data are important for understanding viral hepatitis trends, informing and developing effective public health programs, and monitoring progress toward eliminating viral hepatitis as a public health threat in the United States. For more information about these data, please see Technical Notes.
Compound 530727: 2,6-Difluorobenzoic acid, 2,7-dimethyloct-7-en-5-yn-4-yl ester

Chemical compound data from PubChem database. IUPAC Name: 2,7-dimethyloct-7-en-5-yn-4-yl 2,6-difluorobenzoate. Molecular Formula: C17H18F2O2. Molecular Weight: 292.32. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.